Tiemen R. van Mourik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tiemen R. van Mourik has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Arjan W. Griffioen
Angiogenesis Laboratory, Department of Medical Oncology, VU University Medical Center, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands
1 shared publicationHolger Grüll
Department Minimally Invasive Healthcare, Philips Research, High Tech Campus 11, 5656 AE Eindhoven, The Netherlands
1 shared publication- Holger Grüll
Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands
1 shared publication - Johan Lub
Department Minimally Invasive Healthcare, Philips Research, High Tech Campus 11, 5656 AE Eindhoven, The Netherlands
1 shared publication Judy R. van Beijnum
Angiogenesis Laboratory, Department of Medical Oncology, VU University Medical Center, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands
1 shared publication- Justine F. Simon
Cyclotron Research Centre, University of Liege, Allée du six Août B30, 4000 Sart Tilman, Belgium
1 shared publication
Latest Publications
- 18 May 2017
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 60 (6) , 286-293
Development of a novel, fibrin‐specific PET tracer
Fibrin deposition is observed in several diseases such as atherosclerosis, deep vein thrombosis, and also tumors, where it contributes to the formation of mature tumor stroma. The aim of this study was to develop a gallium‐labeled peptide tracer on the basis of the fibrin‐targeting peptide Epep for PET imaging of fibrin deposition. For this purpose, the peptide Epep was modified with a NOTA moiety for radiolabeling with 67Ga and 68Ga and compared with the earlier validated 111In‐DOTA‐Epep tracer. In vitro binding assays of 67Ga‐NOTA‐Epep displayed an enhanced retention as compared to previously published data showing binding of 111In‐DOTA‐Epep to human (84.0 ± 0.6 vs 66.6 ± 1.4 %Dose) and mouse derived fibrin clots (83.5 ± 1.7 vs 74.2 ± 2.4% Dose). In vivo blood kinetics displayed a bi‐phasic elimination profile (t1/2,α = 2.6 ± 1.0 minutes and t1/2,β = 15.8 ± 1.3 minutes) and ex vivo biodistribution showed low blood values at 4 hours post injection and a low uptake in nontarget tissue (in vitro and in vivo studies, gallium‐labeled Epep displays the potential for further development towards a PET tracer for fibrin deposition.
- 18 May 2017
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 60 (6) , 286-293
Development of a novel, fibrin‐specific PET tracer
Fibrin deposition is observed in several diseases such as atherosclerosis, deep vein thrombosis, and also tumors, where it contributes to the formation of mature tumor stroma. The aim of this study was to develop a gallium‐labeled peptide tracer on the basis of the fibrin‐targeting peptide Epep for PET imaging of fibrin deposition. For this purpose, the peptide Epep was modified with a NOTA moiety for radiolabeling with 67Ga and 68Ga and compared with the earlier validated 111In‐DOTA‐Epep tracer. In vitro binding assays of 67Ga‐NOTA‐Epep displayed an enhanced retention as compared to previously published data showing binding of 111In‐DOTA‐Epep to human (84.0 ± 0.6 vs 66.6 ± 1.4 %Dose) and mouse derived fibrin clots (83.5 ± 1.7 vs 74.2 ± 2.4% Dose). In vivo blood kinetics displayed a bi‐phasic elimination profile (t1/2,α = 2.6 ± 1.0 minutes and t1/2,β = 15.8 ± 1.3 minutes) and ex vivo biodistribution showed low blood values at 4 hours post injection and a low uptake in nontarget tissue (in vitro and in vivo studies, gallium‐labeled Epep displays the potential for further development towards a PET tracer for fibrin deposition.
- 1 January 2015
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 89, 279-295
Novel analogs of antitumor agent calixarene 0118: Synthesis, cytotoxicity, click labeling with 2-[18F]fluoroethylazide, and in vivo evaluation
- 1 January 2015
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 89, 279-295
Novel analogs of antitumor agent calixarene 0118: Synthesis, cytotoxicity, click labeling with 2-[18F]fluoroethylazide, and in vivo evaluation